文献速递免疫规划卫生政策与健康促进

两剂mRNA新冠疫苗接种对免疫功能低下成人新冠相关住院的保护效果——九州,2021年1月至9月

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-11-05

分析VISION网络九州187家医院2021年1月17日至9月5日≥18岁新冠样疾病住院者数据,采用检测阴性设计比较20,101例免疫功能低下成人(53%完成两剂接种)与69,116例免疫功能正常成人(43%完成两剂接种)。完成两剂mRNA疫苗接种对新冠相关住院的保护效果在免疫功能低下组为77%(95%CI=74%-80%),低于免疫功能正常组的90%(95%CI=89%-91%)。

要点

  • 完成两剂mRNA疫苗接种对新冠相关住院的保护效果在免疫功能低下成人为77%(95%CI=74%-80%),低于免疫功能正常成人的90%(95%CI=89%-91%)。
  • 保护效果在器官或干细胞移植受者中为59%,在风湿性或炎症性疾病患者中为81%。
  • 免疫功能低下者应接种3剂及加强针,并采取非药物干预措施。

核心结论

  • 免疫功能低下者接种mRNA新冠疫苗有获益,但对重症新冠结局的保护低于免疫功能正常者,且不同免疫功能低下亚组间保护效果存在差异。

研究设计与样本

  • 基于VISION网络九州187家医院2021年1月17日至9月5日≥18岁新冠样疾病住院者数据,采用检测阴性设计比较20,101例免疫功能低下成人(10,564例[53%]完成两剂接种)与69,116例免疫功能正常成人(29,456例[43%]完成两剂接种)。

主要发现

  • 完成两剂mRNA疫苗接种对新冠相关住院的保护效果在免疫功能低下组为77%(95%CI=74%-80%),在免疫功能正常组为90%(95%CI=89%-91%)。
  • 该差异在不同mRNA疫苗产品、年龄组及住院时间相对于Delta变异株优势期的条件下均持续存在。
  • 保护效果在不同免疫功能低下亚组间存在差异,范围为59%(器官或干细胞移植受者)至81%(风湿性或炎症性疾病患者)。

关键数值与推荐

  • 完成两剂mRNA新冠疫苗系列且第二剂在索引住院日期前≥14天定义为完全接种。
  • 免疫功能低下成人的保护效果为77%(95%CI=74%-80%),免疫功能正常成人为90%(95%CI=89%-91%)。
  • 器官或干细胞移植受者的保护效果为59%,风湿性或炎症性疾病患者为81%。

临床怎么用

  • 免疫功能低下者接种mRNA新冠疫苗应接种3剂及加强针,符合CDC建议。
  • 免疫功能低下者应采取非药物干预措施。
  • 免疫功能低下者若感染,应密切监测并考虑早期使用经证实可预防重症结局的疗法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunocompromised persons, defined as those with suppressed humoral or cellular immunity resulting from health conditions or medications, account for approximately 3% of the U.S. adult population (1). Immunocompromised adults are at increased risk for severe COVID-19 outcomes (2) and might not acquire the same level of protection from COVID-19 mRNA vaccines as do immunocompetent adults (3,4). To evaluate vaccine effectiveness (VE) among immunocompromised adults, data from the VISION Network* on hospitalizations among persons aged ≥18 years with COVID-19-like illness from 187 hospitals in nine states during January 17-September 5, 2021 were analyzed. Using selected discharge diagnoses,† VE against COVID-19-associated hospitalization conferred by completing a 2-dose series of an mRNA COVID-19 vaccine ≥14 days before the index hospitalization date§ (i.e., being fully vaccinated) was evaluated using a test-negative design comparing 20,101 immunocompromised adults (10,564 [53%] of whom were fully vaccinated) and 69,116 immunocompetent adults (29,456 [43%] of whom were fully vaccinated). VE of 2 doses of mRNA COVID-19 vaccine against COVID-19-associated hospitalization was lower among immunocompromised patients (77%; 95% confidence interval [CI] = 74%-80%) than among immunocompetent patients (90%; 95% CI = 89%-91%). This difference persisted irrespective of mRNA vaccine product, age group, and timing of hospitalization relative to SARS-CoV-2 (the virus that causes COVID-19) B.1.617.2 (Delta) variant predominance in the state of hospitalization. VE varied across immunocompromising condition subgroups, ranging from 59% (organ or stem cell transplant recipients) to 81% (persons with a rheumatologic or inflammatory disorder). Immunocompromised persons benefit from mRNA COVID-19 vaccination but are less protected from severe COVID-19 outcomes than are immunocompetent persons, and VE varies among immunocompromised subgroups. Immunocompromised persons receiving mRNA COVID-19 vaccines should receive 3 doses and a booster, consistent with CDC recommendations (5), practice nonpharmaceutical interventions, and, if infected, be monitored closely and considered early for proven therapies that can prevent severe outcomes.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34735426. doi:10.15585/mmwr.mm7044e3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。